Team:NJU China

From 2013.igem.org

(Difference between revisions)
Line 1: Line 1:
-
<!-- *** What falls between these lines is the Alert Box!  You can remove it from your pages once you have read and understood the alert *** -->
 
<html>
<html>
-
<div id="box" style="width: 700px; margin-left: 137px; padding: 5px; border: 3px solid #000; background-color: #fe2b33;">
+
<head>
-
<div id="template" style="text-align: center; font-weight: bold; font-size: large; color: #f6f6f6; padding: 5px;">
+
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
-
This is a template page. READ THESE INSTRUCTIONS.
+
<script src="http://cdn.jquerytools.org/1.2.5/full/jquery.tools.min.js?foo"></script>
-
</div>
+
-
<div id="instructions" style="text-align: center; font-weight: normal; font-size: small; color: #f6f6f6; padding: 5px;">
+
-
You are provided with this team page template with which to start the iGEM season.  You may choose to personalize it to fit your team but keep the same "look." Or you may choose to take your team wiki to a different level and design your own wiki.  You can find some examples <a href="https://2009.igem.org/Help:Template/Examples">HERE</a>.
+
-
</div>
+
-
<div id="warning" style="text-align: center; font-weight: bold; font-size: small; color: #f6f6f6; padding: 5px;">
+
-
You <strong>MUST</strong> have all of the pages listed in the menu below with the names specified. PLEASE keep all of your pages within your teams namespace.
+
-
</div>
+
-
</div>
+
-
</html>
+
-
<!-- *** End of the alert box *** -->
+
<link rel="stylesheet" type="text/css" href="http://cs.wellesley.edu/~hcilab/iGEM2012/css/Team.css">
 +
<STYLE type="text/css">
 +
/* MAIN STYLE DEFINITIONS */
 +
a{
 +
color:#870203;
 +
-webkit-transition-duration:0.3s;
 +
-moz-transition-duration:0.3s;
 +
-o-transition-duration:0.3s;
 +
}
 +
 
 +
a:hover {
 +
color:#3d3f3c;
 +
}
 +
 
 +
a:visited{
 +
color:#870203;
 +
}
 +
 
 +
td
 +
{
 +
font-family: Helvetica;
 +
font-size: 10pt;
 +
vertical-align: top;
 +
text-align: left;
 +
padding-right: 10px;
 +
}
 +
 
 +
tr
 +
{
 +
vertical-align: top;
 +
}
 +
 
 +
H1 {
 +
    font-family: Helvetica;
 +
    text-transform: uppercase;
 +
    color: #3d3f3c;
 +
    text-align: left;
 +
    }
 +
 
 +
 
 +
H4 {
 +
    font-family: Helvetica;
 +
    text-transform: uppercase;
 +
    color: #3d3f3c;
 +
    text-align: left;
 +
    }
 +
 
 +
/* CONTENT HEADING STYLES - overrides some main.css styling */
 +
 
 +
H6 {
 +
font-family:'Caviar Dreams';
 +
font-size:30px;
 +
font-weight:500;
 +
text-align:left;
 +
text-transform:uppercase;
 +
color: #3d3f3c;
 +
border-bottom:1px solid orangered;
 +
padding-bottom:10px;
 +
margin:15px 0;
 +
}
 +
 
 +
H1, H3 {
 +
font-family:'Source Sans Pro';
 +
font-weight:600;
 +
text-transform:uppercase;
 +
}
 +
 
 +
H1 {
 +
font-size:20px;
 +
border:none;
 +
}
 +
 
 +
img.headshot {
 +
width: 100px;
 +
height: auto;
 +
vertical-align: text-top;
 +
}
 +
 
 +
 
 +
 
 +
body {
 +
background:#fff;
 +
font-family: Helvetica;
 +
}
 +
 
 +
content {
 +
background: transparent;
 +
}
 +
 
 +
#tracking_nav
 +
{
 +
margin: 0px 0px 0px 950px;
 +
position: fixed;
 +
color:#bababa;
 +
border: 1px solid #3d3f3c;
 +
background:#3d3f3c;
 +
font-size: 16pt;
 +
padding: 5px;
 +
line-height: 120%;
 +
}
 +
 
 +
#tracking_nav a { color:#ffffff; text-transform: lowercase;font-size: 16pt;}
 +
#tracking_nav a:hover {background:#bababa;}
 +
 
 +
#parts_table
 +
{
 +
border: 1px solid #870203;
 +
border-collapse: collapse;
 +
width: 70%;
 +
margin: auto;
 +
}
 +
 
 +
#parts_table td
 +
{
 +
text-align: center;
 +
margin: 5px;
 +
border: 1px solid #870203;
 +
 +
}
 +
 
 +
#parts_table th
 +
{
 +
background-color: #bababa;
 +
border: 1px solid #870203;
 +
color: #ffffff;
 +
}
 +
 
 +
.table_part
 +
{
 +
vertical-align: middle;
 +
}
 +
 
 +
/* HEADER STYLES: banner, navbar, etc. */
 +
#banner { width:300px; display:block; float:left; }
 +
#banner img { width:100%; }
 +
 
 +
ul#nav {
 +
width:600px;
 +
margin:0 0 0 30px;
 +
position:relative;
 +
}
 +
 
 +
#nav li {
 +
color: #bbb;
 +
background-color:none;
 +
margin: 0 50px 0 0;
 +
float: left;
 +
position: relative;
 +
list-style: none;
 +
text-transform:uppercase;
 +
}
 +
#nav li:last-child { margin:0; }
 +
 
 +
/* main level link */
 +
#nav a {
 +
font-family:'Source Sans Pro', sans-serif;
 +
font-size:10pt;
 +
font-weight:500;
 +
line-height:110%;
 +
color: inherit;
 +
text-decoration: none;
 +
display: block;
 +
padding: 0 0 0 5px;
 +
margin: 0;
 +
}
 +
 
 +
ul#nav > li > a {
 +
line-height:12px;
 +
border-left:solid 2px #bbb;
 +
padding:0 0 0 3px;
 +
}
 +
 
 +
#nav a:hover {
 +
/*background-color: #870203;
 +
color: #ffffff;*/
 +
}
 +
 
 +
/* main level link hover */
 +
#nav .current a, #nav li:hover > a {
 +
color: #000;
 +
border-color:orangered;
 +
}
 +
 
 +
/* sub levels link hover */
 +
#nav ul li:hover a, #nav li:hover li a {
 +
border: none;
 +
/*background-color: #FA9D1C;*/
 +
color:#000;
 +
}
 +
 
 +
#nav ul a:hover {
 +
color: orangered !important;
 +
/*background: #fff url(img/gradient.png) repeat-x 0 -100px !important;
 +
text-shadow: 0 1px 1px rgba(0,0,0, .1);*/
 +
}
 +
 
 +
 
 +
/* dropdown */
 +
#nav li:hover > ul {
 +
/*display: block;*/
 +
opacity:1;
 +
margin:0;
 +
background-color: none;
 +
z-index:0;
 +
}
 +
 
 +
/* level 2 list */
 +
#nav ul {
 +
/*display: none;*/
 +
opacity:0;
 +
margin: 20px 0 0 0;
 +
padding: 7px 0 0 0;
 +
width: 205px;
 +
position: absolute;
 +
left: 0;
 +
z-index:-1;
 +
-webkit-transition-duration:0.5s;
 +
-moz-transition-duration:0.5s;
 +
-o-transition-duration:0.5s;
 +
}
 +
#nav ul li {
 +
float: none;
 +
margin: 0;
 +
padding: 0;
 +
}
 +
 
 +
#nav ul a {
 +
font-weight: normal;
 +
/*text-shadow: 0 1px 0 #fff;*/
 +
}
 +
 
 +
/* clearfix */
 +
#nav:after {
 +
content: ".";
 +
display: block;
 +
clear: both;
 +
visibility: hidden;
 +
line-height: 0;
 +
height: 0;
 +
}
 +
#nav {
 +
display: inline-block;
 +
}
 +
html[xmlns] #nav {
 +
display: block;
 +
}
 +
 +
* html #nav {
 +
height: 1%;
 +
}
 +
 
 +
/* pinterest like photo grid for social page*/
 +
 
 +
/*
 +
body {
 +
background: url(http://subtlepatterns.com/patterns/scribble_light.png) ;
 +
}
 +
*/
 +
 
 +
#wrapper {
 +
width: 90%;
 +
max-width: 1100px;
 +
min-width: 800px;
 +
margin: 50px auto;
 +
}
 +
 
 +
#columns {
 +
-webkit-column-count: 3;
 +
-webkit-column-gap: 10px;
 +
-webkit-column-fill: auto;
 +
-moz-column-count: 3;
 +
-moz-column-gap: 10px;
 +
-moz-column-fill: auto;
 +
column-count: 3;
 +
column-gap: 15px;
 +
column-fill: auto;
 +
}
 +
 
 +
.pin {
 +
display: inline-block;
 +
background: #FEFEFE;
 +
border: 2px solid #FAFAFA;
 +
box-shadow: 0 1px 2px rgba(34, 25, 25, 0.4);
 +
margin: 0 2px 15px;
 +
-webkit-column-break-inside: avoid;
 +
-moz-column-break-inside: avoid;
 +
column-break-inside: avoid;
 +
padding: 15px;
 +
padding-bottom: 5px;
 +
background: -webkit-linear-gradient(45deg, #FFF, #F9F9F9);
 +
opacity: 1;
 +
 +
-webkit-transition: all .2s ease;
 +
-moz-transition: all .2s ease;
 +
-o-transition: all .2s ease;
 +
transition: all .2s ease;
 +
}
 +
 
 +
.pin img {
 +
width: 100%;
 +
border-bottom: 1px solid #ccc;
 +
padding-bottom: 15px;
 +
margin-bottom: 5px;
 +
}
 +
 
 +
.pin p {
 +
font: 12px/18px Arial, sans-serif;
 +
color: #333;
 +
margin: 0;
 +
}
 +
 
 +
@media (min-width: 960px) {
 +
#columns {
 +
-webkit-column-count: 4;
 +
-moz-column-count: 4;
 +
column-count: 4;
 +
}
 +
}
 +
 
 +
@media (min-width: 1100px) {
 +
#columns {
 +
-webkit-column-count: 5;
 +
-moz-column-count: 5;
 +
column-count: 5;
 +
}
 +
}
 +
 
 +
#columns:hover .pin:not(:hover) {
 +
opacity: 0.4;
 +
}
 +
</STYLE>
 +
 
 +
<link href='http://fonts.googleapis.com/css?family=Source+Sans+Pro:400,600' rel='stylesheet' type='text/css'>
 +
 
 +
<!--Start NavBar-->
 +
<ul id="nav">
 +
    <li><a href="https://2013.igem.org/Team:NJU_China">Home</a></li>
 +
 +
    <li><a href="https://2013.igem.org/Team:NJU_China/Team">Team</a>
 +
        <!--<ul>
 +
    <li><a href="https://2013.igem.org/Team:Wellesley_Desyne/Team">Team Members</a></li>
 +
    <li><a href="https://2013.igem.org/Team:Wellesley_Desyne/Notebook">Notebook</a></li>
 +
            <li><a href="https://2013.igem.org/Team:Wellesley_Desyne/Acknowledgement">Acknowledgement</a></li>
 +
    <li><a href="https://2013.igem.org/Team:Wellesley_Desyne/Tips_Tricks">Tips & Tricks</a></li>
 +
    <li><a href="https://2013.igem.org/Team:Wellesley_Desyne/Social">Fun</a></li>
 +
</ul>-->
 +
    </li>
 +
 
 +
    <li><a href="https://2013.igem.org/Team:NJU_China/Project">Project</a>
 +
        <ul>
 +
    <li><a href="http://https://2013.igem.org/Team:NJU_China/Project#Overall_project">Project Overview</a></li>
 +
            <li><a https://2013.igem.org/Team:NJU_China/Project#Project_Details">Project_Details</a></li>
 +
            <li><a https://2013.igem.org/Team:NJU_China/Project#Part_2">Part_2</a></li>
 +
            <li><a https://2013.igem.org/Team:NJU_China/Project#The_Experiments">The_Experiments</a></li>
 +
            <li><a https://2013.igem.org/Team:NJU_China/Project#Part_3">Part_3</a></li>
 +
            <li><a https://2013.igem.org/Team:NJU_China/Project#Results">Results</a></li>
 +
        </ul>
 +
    </li>
 +
 +
    <li><a href="https://2013.igem.org/Team:NJU_China/Parts">Parts</a></li>
 +
 
 +
    <li><a href="https://2013.igem.org/Team:NJU_China/Modeling">Modeling</a></li>
 +
   
 +
    <li><a href="https://2013.igem.org/Team:NJU_China/Notebook">Notebook</a></li>
 +
 
 +
    <li><a href="https://2013.igem.org/Team:NJU_China/Safety">Safety</a></li>
 +
 
 +
    <li><a href="https://2013.igem.org/Team:NJU_China/Attributions">Attributions</a></li>
 +
   
 +
</ul>
 +
<!--End NavBar--> 
 +
</body>
 +
</html>
Line 20: Line 382:
{|align="justify"
{|align="justify"
-
                                         
 
-
|You can write a background of your team here.  Give us a background of your team, the members, etc.  Or tell us more about something of your choosing.
+
[[Image:NJU China TeamLogo.png|1000px]]                                      
-
|[[Image:NJU_China_logo.png|200px|right|frame]]
+
 
-
|-
+
'''Biomissile'''
-
|
+
Site-specific drug delivery has always been a challenge in drug treatment. It is acknowledged that a new system needs to be developed in order to overcome the poor targeting, low effectiveness and low safety of present ones.  
-
''Tell us more about your project. Give us background.  Use this as the abstract of your project. Be descriptive but concise (1-2 paragraphs)''
+
 
-
|[[Image:NJU_China_team.png|right|frame|Your team picture]]
+
|Microvesicles (MV) are lipid bilayer vesicles which are naturally secreted by almost every types of cells, playing a role in transportation of mRNA, miRNA, and proteins between cells. We are trying to construct a system which employs the freely movable MV as a vehicle to achieve site-specific drug delivery.
-
|-
+
 
-
|
+
By transfecting recombinant plasmids into the human embryonic kidney cell (293T cell) which can produce large amounts of microvesicles, we are hoping to add targeting protein onto the surface of the MV to endow it with ability of site-specific recognition in order to realize the site-specificity.
 +
 
 +
siRNAs are known to play a significant role in RNA interference by degrading targeted RNA. Similarly, by transfecting the 293T cells with siRNA plasmids, we enable them to express anti-viral siRNAs which can be encapsulated into the MVs.
 +
 
 +
Our modified MVs are just like the missiles, which can destroy viral RNA and target specially to viral infected cells. So we call it “Biomissile”.
 +
|[[Image:NJU China Team.JPG|500px|right]]
 +
|-|
|align="center"|[[Team:NJU_China | Team NJU_China]]
|align="center"|[[Team:NJU_China | Team NJU_China]]
|}
|}
-
<!--- The Mission, Experiments --->
+
<!--- The Mission, Experiments
{| style="color:#1b2c8a;background-color:#0c6;" cellpadding="3" cellspacing="1" border="1" bordercolor="#fff" width="62%" align="center"
{| style="color:#1b2c8a;background-color:#0c6;" cellpadding="3" cellspacing="1" border="1" bordercolor="#fff" width="62%" align="center"
Line 45: Line 412:
!align="center"|[[Team:NJU_China/Safety|Safety]]
!align="center"|[[Team:NJU_China/Safety|Safety]]
!align="center"|[[Team:NJU_China/Attributions|Attributions]]
!align="center"|[[Team:NJU_China/Attributions|Attributions]]
-
|}
+
|}--->

Revision as of 11:23, 14 July 2013


NJU China TeamLogo.pngBiomissile Site-specific drug delivery has always been a challenge in drug treatment. It is acknowledged that a new system needs to be developed in order to overcome the poor targeting, low effectiveness and low safety of present ones.
Microvesicles (MV) are lipid bilayer vesicles which are naturally secreted by almost every types of cells, playing a role in transportation of mRNA, miRNA, and proteins between cells. We are trying to construct a system which employs the freely movable MV as a vehicle to achieve site-specific drug delivery.

By transfecting recombinant plasmids into the human embryonic kidney cell (293T cell) which can produce large amounts of microvesicles, we are hoping to add targeting protein onto the surface of the MV to endow it with ability of site-specific recognition in order to realize the site-specificity.

siRNAs are known to play a significant role in RNA interference by degrading targeted RNA. Similarly, by transfecting the 293T cells with siRNA plasmids, we enable them to express anti-viral siRNAs which can be encapsulated into the MVs.

Our modified MVs are just like the missiles, which can destroy viral RNA and target specially to viral infected cells. So we call it “Biomissile”.

NJU China Team.JPG
Team NJU_China


Retrieved from "http://2013.igem.org/Team:NJU_China"